Laninamivir (BioDeep_00000180385)
human metabolite blood metabolite
代谢物信息卡片
化学式: C13H22N4O7 (346.1488422)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 7.51%
分子结构信息
SMILES: CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N
InChI: InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)
描述信息
同义名列表
9 个代谢物同义名
5-(Acetylamino)-4-((aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid; 4-Carbamimidamido-2-(2,3-dihydroxy-1-methoxypropyl)-3-[(1-hydroxyethylidene)amino]-3,4-dihydro-2H-pyran-6-carboxylate; 4-[(diaminomethylidene)amino]-2-(2,3-dihydroxy-1-methoxypropyl)-3-acetamido-3,4-dihydro-2H-pyran-6-carboxylic acid; 3-acetamido-4-(diaminomethylideneamino)-2-(2,3-dihydroxy-1-methoxypropyl)-3,4-dihydro-2H-pyran-6-carboxylic acid; Laninamivir octanoate monohydrate; Laninamivir octanoate hydrate; Laninamivir trifluoroacetate; Laninamivir octanoate; Laninamivir
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Takanori Tomozawa, Kazuki Hoshino, Makoto Yamashita, Shuku Kubo. Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2019 Aug; 25(8):584-588. doi:
10.1016/j.jiac.2019.02.023. [PMID: 30935767] - R Farrukee, J Butler, P C Reading, A C Hurt. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Antiviral research.
2019 08; 168(?):68-75. doi:
10.1016/j.antiviral.2019.05.009. [PMID: 31132385] - Khristine Kaith S Lloren, Jin Jung Kwon, Won-Suk Choi, Ju Hwan Jeong, Su Jeong Ahn, Young Ki Choi, Yun Hee Baek, Min-Suk Song. In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.
Journal of virology.
2019 03; 93(6):. doi:
10.1128/jvi.01825-18. [PMID: 30602610] - Kaoru Toyama, Hidetoshi Furuie, Hitoshi Ishizuka. Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
Antimicrobial agents and chemotherapy.
2018 01; 62(1):. doi:
10.1128/aac.01722-17. [PMID: 29061751] - Siriwan Charyasriwong, Takahiro Haruyama, Nobuyuki Kobayashi. In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection.
Drug discoveries & therapeutics.
2016 ; 10(4):201-10. doi:
10.5582/ddt.2016.01045. [PMID: 27558282] - Jennifer L McKimm-Breschkin, Susan Barrett. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
Antiviral research.
2015 Feb; 114(?):62-6. doi:
10.1016/j.antiviral.2014.12.004. [PMID: 25499124] - K Sleeman, V P Mishin, Z Guo, R J Garten, A Balish, A M Fry, J Villanueva, J Stevens, L V Gubareva. Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.
Antimicrobial agents and chemotherapy.
2014; 58(4):2045-51. doi:
10.1128/aac.02556-13. [PMID: 24449767] - Daisuke Tamura, Ha T Nguyen, Katrina Sleeman, Marnie Levine, Vasiliy P Mishin, Hua Yang, Zhu Guo, Margaret Okomo-Adhiambo, Xiyan Xu, James Stevens, Larisa V Gubareva. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Antimicrobial agents and chemotherapy.
2013 Dec; 57(12):6141-6. doi:
10.1128/aac.01364-13. [PMID: 24080660] - Seiichiro Fujisaki, Masaki Imai, Emi Takashita, Tae Taniwaki, Hong Xu, Noriko Kishida, Masaru Yokoyama, Hironori Sato, Masato Tashiro, Takato Odagiri. Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
2013 Oct; 19(5):891-5. doi:
10.1007/s10156-013-0589-6. [PMID: 23529501] - Kazutaka Yoshihara, Hitoshi Ishizuka, Yuichi Kubo. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
Drug metabolism and pharmacokinetics.
2013; 28(5):416-26. doi:
10.2133/dmpk.dmpk-12-rg-115. [PMID: 23574886] - Seiichiro Fujisaki, Emi Takashita, Masaru Yokoyama, Tae Taniwaki, Hong Xu, Noriko Kishida, Hironori Sato, Masato Tashiro, Masaki Imai, Takato Odagiri. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Biochemical and biophysical research communications.
2012 Dec; 429(1-2):51-6. doi:
10.1016/j.bbrc.2012.10.095. [PMID: 23131559] - Hitoshi Ishizuka, Kaoru Toyama, Satoshi Yoshiba, Hiromi Okabe, Hidetoshi Furuie. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Antimicrobial agents and chemotherapy.
2012 Jul; 56(7):3873-8. doi:
10.1128/aac.06456-11. [PMID: 22526307] - Masaya Fukushi, Makoto Yamashita, Tohru Miyoshi-Akiyama, Shuku Kubo, Kenji Yamamoto, Koichiro Kudo. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
PloS one.
2012; 7(8):e42419. doi:
10.1371/journal.pone.0042419. [PMID: 22879974] - Hitoshi Ishizuka, Satoshi Yoshiba, Kazutaka Yoshihara, Hiromi Okabe. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Journal of clinical pharmacology.
2011 Feb; 51(2):243-51. doi:
10.1177/0091270010361914. [PMID: 20197485] - Hitoshi Ishizuka, Satoshi Yoshiba, Hiromi Okabe, Kazutaka Yoshihara. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
Journal of clinical pharmacology.
2010 Nov; 50(11):1319-29. doi:
10.1177/0091270009356297. [PMID: 20145259] - Phillip Andrew Reece. Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Postgraduate medicine.
2010 Sep; 122(5):134-41. doi:
10.3810/pgm.2010.09.2210. [PMID: 20861597] - K Koyama, M Takahashi, N Nakai, H Takakusa, T Murai, M Hoshi, N Yamamura, N Kobayashi, O Okazaki. Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2010 Mar; 40(3):207-16. doi:
10.3109/00498250903447691. [PMID: 20146556]